I think it would be best to swing trade this for a few months. I'm on record for being petty accurate so far. I'm suggesting to buy now and sell half of position @ 3.75 and watch it fall back to 3.50 or a little lower than repeat with adding that half that you sold. GL
Unknown & deep brutally Undervalued .... SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / NO Debt / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.9 Million Cash: $12.6 Million Price: $5.50
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment •Mondoxyne for severe acne –launched late 2015 •Ceramax for skin repair in atopic dermatitis–launched in April 2016 •SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017 •Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
Matinas (MTNB) Bio to seek commercialization partner for dyslipidemia med MAT9001; shares up 1% Company says MAT9001 is more effective than Amarin's Vascepa based on comparative studies, trying to get the word out before reduce it trials come to an end. Much of this was a C&P from a SA article that could be googled I am sure. Looks like a possible patent infringement situation. Any body got some ideas? Wouldn't want our party broken up because some other company using prescription strength Omega 3's got the same idea? Gonna dig some more, this is hot off the SA bongo hotline this morning.
AMRN lawsuit is a winner for this stock
Why is the U.S. International Trade Commission seeking a ban on the importation of omega-3 dietary supplements that are mainly comprised of the ester form of omega-3 called EPA? If Amarin's wins lawsuit, is this a milestone achievement for better outcome in the future?
XBI = Bio tk and drugs ETF matched 52 week high today = good for the sector [ they rotated out of TECH in to Bio teck started days and days ago ]
Above the 200 day mov T / A Boys like that
Loving the upward momentum after falling all that way after the big spike.
Investor relations [ FAQ ] = some info re law suit they filed with Inter national trade comm yesterday news more will be avialble via ITC web site see bottom ish of yesterdays news release.
Have not looked as of yet
T / A Wise went from over bought to over sold = im long small $ 3.32 based on chart only [ doing DD ] now. currently RSI = 554 at $ 3.37 lets see if we can get to a 70 RSI or better
New to this so not sure re street est but this yr vs next looks pretty good, since this yr is almost done [ time flys ] time will tell if the street is behind the curve or not, new here = no basis for history of street accuracy
Always good to read the cc call transripts at seeking alpha some times its on yahoo as well as well as the cc call it self
Dang, I joined at 4.30 thinking I was a damn genius. Now I'm down 500 dollars and hoping this goes up sometime preferably sooner than the time between the last two jumps. I don't want to wait years to get my money back.
Why do these companies like AMRN give free stock to management in huge numbers and they turn around and sell them at market. That's in addition to their salary and bonus. These guys at AMRN are getting filthy rich selling their free stock. Why don't they at least hold the stock? BECAUSE THEY KNOW THERE IS NOTHING HERE!
I believe the recent price action is indicative of short term investors getting out due to the continuation of the REDUCE-IT trial. But common sense would dictate the chance of early cessation were very low. I think some consideration should be given to some 'hidden' facts about REDUCE IT that I don't think many have actually thought about with regards to the chances of it actually expanding the labeling for Vascepa. Consider this... When REDUCE IT was initiated, the official company projection for 60% and 100% of 'cardiovascular events' was indicated for 1st half of 2016 and 2nd half of 2017 respectively. Then in August 2016 they added the 80% analysis with projection of 1st half of 2017 and still had 100% in 2nd half of 2017. Now, in the last Press release, they expect the 100%, or the 1,612th event, to occur in early 2018. So it has the appearance that the projected timeframe for these 'cardiovascular events' has taken longer than initially projected, therefore, it provides a potential thought process that might give credence to the idea that the Vascepa arm of the study hasn't had the same frequency of events as the placebo arm. Of course, there's no way to know for sure but is it telling us that Vascepa may be responsible for slowing the rate of events? Isn't that what the study was designed to determine? Read back through the Press Releases and see how the projections have slowly moved further out than originally stated... not by a huge amount but it has been extended now into 2018. I definitely don't like the recent price action but also wonder if maybe there's hope hidden in the data being presented by the DMC in the latest release.
Why were MERCK officers at AMRN headquarters at 5pm yesterday?
Long Island Iced Tea Looks Poised To Benefit From Shift Away From Carbonated Beverages
Long Island Iced Tea is a beverage company that provides premium non-alcoholic ready-to-drink iced tea bottle beverages. The company recently closed a public of
WHAT IS HAPPENING HERE. What kind of news could make this go bearish for an entire week?
All you have to do is click "holders" here on Yahoo for AMRN, then "insider transactions". Insiders are selling like crazy, every chance they get. What does that tell you? Scam stock! Statistics don't lie.
The price action is telling us the market is somewhere between 65% and 85% sure that Reduce-It is a bust. Is that the general belief here?